Witty at OPPI: 'Its only a billion dollars because we fail too often'
This article was originally published in Scrip
OPPI (Organisation of Pharmaceutical Producers of India) annual general meetings over the years have seen many a keynote speaker highlight how Big Pharma invests huge sums in discovery research and why only a robust IPR regime would help them recoup investments and prevent a free ride by generic firms.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.